Clinical value of assessing the response to imatinib monitored by interphase FISH and RQ-PCR for BCR-ABL in peripheral blood for long-term survival of chronic phase CML patients: Results of the Niigata CML-multi-institutional co-operative clinical study

International Journal of Hematology

Volumn 93, Issue 3, 2011, Pages 336-343

  Furukawa, Tatsuo ^a   Narita, Miwako ^b   Koike, Tadashi ^c   Takai, Kazue ^d   Nagai, Koichi ^e   Kobayashi, Masashi ^f   Koyama, Satoru ^g   Seki, Yoshinobu ^h   Takahashi, Hoyu ⁱ   Fujiwara, Masahiro ^j   Kishi, Kenji ^f   Nikkuni, Koji ^d   Isahai, Noriatsu ^e   Higuchi, Wataru ^k   Nomoto, Nobuhiko ^l   Maruyama, Souichi ^m   Masuko, Masayoshi ^b   Kuroha, Takashi ⁿ   Abe, Takashi ⁿ   Toba, Ken ⁿ   Takahashi, Masuhiro ^b   Aizawa, Yoshifusa ⁿ   Shibata, Akira ^m   more..

^a NIIGATA UNIVERSITY MEDICAL AND DENTAL HOSPITAL   (Japan)

^b NIIGATA UNIVERSITY   (Japan)

^c NAGAOKA RED CROSS HOSPITAL   (Japan)

^d NIIGATA CITY GENERAL HOSPITAL   (Japan)

^e Niigata Prefectural Central Hospital   (Japan)

^f Nagaoka Chuo General Hospital   (Japan)

^g Saiseikai Niigata Daini Hospital   (Japan)

^h Niigata Prefectural Shibata Hospital   (Japan)

ⁱ Niigata Prefectural Kamo Hospital   (Japan)

^j Kariwagun General Hospital   (Japan)

^k Tsubame Rosai Hospital   (Japan)

^l Niigata Medical Center   (Japan)

^m Niigata Minami Hospital   (Japan)

ⁿ NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

more..

Author keywords

Interphase fluorescence in situ hybridization; Log reduction; Major molecular response; Molecular response; Real time quantitative polymerase chain reaction

Indexed keywords

BCR ABL PROTEIN; IMATINIB;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL ASSESSMENT; CLINICAL STUDY; CYTOGENETICS; DRUG MONITORING; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; HEMATOLOGIC DISEASE; HUMAN; MAJOR CLINICAL STUDY; NEUTROPHIL; OVERALL SURVIVAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; FUSION PROTEINS, BCR-ABL; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; JAPAN; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; NEUTROPHILS; PIPERAZINES; POLYMERASE CHAIN REACTION; PYRIMIDINES; SURVIVAL RATE; TIME FACTORS;

EID: 79955813237     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-011-0774-2     Document Type: Article

References (26)

1. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408-17. (Pubitemid 44903745)
2. De Lavallade H, Apperley JF, Khorashad JS, Milojkovic D, Reid AG, Bua M, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol. 2008;26:3358-63.
3. Kantarjian H, O'Brien S, Shan J, Huang X, Garcia-Manero G, Faderl S, et al. Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions? Cancer. 2008;112:837-45.
4. Marin D, Milojkovic D, Olavarria E, Khorashad JS, de Lavallade H, Reid AG, et al. European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood. 2008;112:4437-44.
5. Alvarado Y, Kantarjian H, O'Brien S, Faderl S, Borthakur G, Burger J, et al. Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase. Cancer. 2009;115:3709-18.
6. Clark RE. Facts and uncertainties in monitoring treatment response in chronic myeloid leukaemia. Leuk Res. 2009;33:1151-5.
7. Deininger MW. Milestones and monitoring in patients with CML treated with imatinib. Hematology Am Soc Hematol Educ Program. 2008;419-26.
8. Baccarani M, Pane F, Saglio G. Monitoring treatment of chronic myeloid leukemia. Haematologica. 2008;93:161-9.
9. Reinhold U, Hennig E, Leiblein S, Niederwieser D, Deininger MW. FISH for BCR-ABL on interphases of peripheral blood neutrophils but not of unselected white cells correlates with bone marrow cytogenetics in CML patients treated with imatinib. Leukemia. 2003;17:1925-9. (Pubitemid 37322119)
10. Takahashi N, Miura I, Kobayashi Y, Kume M, Yoshioka T, Otane W, et al. Fluorescence in situ hybridization monitoring of BCR-ABL-positive neutrophils in chronic-phase chronic myeloid leukemia patients during the primary stage of imatinib mesylate therapy. Int J Hematol. 2005;81:235-41. (Pubitemid 41364489)
11. Kantarjian HM, Talpaz M, Cortes J, O'Brien S, Faderl S, Thomas D, et al. Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia. Clin Cancer Res. 2003;9:160-6. (Pubitemid 36109728)
12. Lange T, Bumm T, Otto S, Al-Ali HK, Kovacs I, Krug D, et al. Quantitative reverse transcription polymerase chain reaction should not replace conventional cytogenetics for monitoring patients with chronic myeloid leukemia during early phase of imatinib therapy. Haematologica. 2004;89:49-57. (Pubitemid 38165855)
13. Ross DM, Branford S, Moore S, Hughes TP. Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL. Leukemia. 2006;20:664-70.
14. Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006;108:1809-20. (Pubitemid 44394987)
15. Osumi K, Fukui T, Kiyoi H, Kasai M, Kodera Y, Kudo K, et al. Rapid screening of leukemia fusion transcripts in acute leukemia by real-time PCR. Leuk Lymphoma. 2002;43:2291-9. (Pubitemid 35386151)
16. Yokota H, Tsuno NH, Tanaka Y, Fukui T, Kitamura K, Hirai H, et al. Quantification of minimal residual disease in patients with e1a2 BCR-ABL-positive acute lymphoblastic leukemia using a real-time RT-PCR assay. Leukemia. 2002;16:1167-75. (Pubitemid 34618855)
17. Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003;349:1423-32. (Pubitemid 37211057)
18. Lucas CM, Wang L, Austin GM, Knight K, Watmough SJ, Shwe KH, et al. A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials. Leukemia. 2008;22:1963-6.
19. Goldman JM. Initial treatment for patients with CML. Hematology Am Soc Hematol Educ Program. 2009;453-60.
20. Kantarjian HM, Talpaz M, O'Brien S, Jones D, Giles F, Garcia-Manero G, et al. Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. Blood. 2006;108:1835-40. (Pubitemid 44394991)
21. Iacobucci I, Saglio G, Rosti G, Testoni N, Pane F, Amabile M, et al. Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. Clin Cancer Res. 2006;12:3037-42. (Pubitemid 43837348)
22. Press RD, Love Z, Tronnes AA, Yang R, Tran T, Mongoue-Tchokote S, et al. BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML. Blood. 2006;107:4250-6. (Pubitemid 43801348)
23. Palandri F, Iacobucci I, Soverini S, Castagnetti F, Poerio A, Testoni N, et al. Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response. Clin Cancer Res. 2009;15:1059-63.
24. Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006;108:28-37. (Pubitemid 43990609)
25. Beillard E, Pallisgaard N, van der Velden VH, Bi W, Dee R, van der Schoot E, et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program. Leukemia. 2003;17:2474-86.
26. Hardling M, Wei Y, Palmqvist L, Swolin B, Stockelberg D, Gustavsson B, et al. Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate. Med Oncol. 2004;21:349-58. (Pubitemid 40065486)